Published in Cancer Res on October 15, 2005
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Identification of cells initiating human melanomas. Nature (2008) 8.28
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19
Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells (2009) 4.08
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A (2007) 3.20
The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol (2007) 3.14
Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A (2010) 2.89
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer (2008) 2.58
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst (2009) 2.39
The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer (2010) 2.20
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One (2011) 1.87
Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78
The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells (2008) 1.70
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
MicroRNAs, cancer and cancer stem cells. Cancer Lett (2010) 1.65
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res (2010) 1.59
Gastric cancer stem cells. J Clin Oncol (2008) 1.59
Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett (2009) 1.59
microRNA and stem cell function. Cell Tissue Res (2007) 1.54
The in vitro spheroid melanoma cell culture assay: cues on tumor initiation? J Invest Dermatol (2010) 1.53
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol (2008) 1.49
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Reactive oxygen species in cancer stem cells. Antioxid Redox Signal (2012) 1.44
Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol (2011) 1.43
Understanding the cancer stem cell. Br J Cancer (2010) 1.42
Clonogenic cell subpopulations maintain congenital melanocytic nevi. J Invest Dermatol (2014) 1.42
What Do We Learn from Spheroid Culture Systems? Insights from Tumorspheres Derived from Primary Colon Cancer Tissue. PLoS One (2016) 1.40
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One (2009) 1.40
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res (2009) 1.38
Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev (2008) 1.36
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer (2010) 1.35
Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J (2011) 1.33
Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res (2011) 1.33
Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res (2008) 1.33
Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31
Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med (2009) 1.30
Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia (2007) 1.29
Generation of human melanocytes from induced pluripotent stem cells. PLoS One (2011) 1.27
Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer (2012) 1.27
Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol (2010) 1.27
Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene (2010) 1.26
The biology of head and neck cancer stem cells. Oral Oncol (2011) 1.25
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol (2011) 1.25
A gene expression profile of stem cell pluripotentiality and differentiation is conserved across diverse solid and hematopoietic cancers. Genome Biol (2012) 1.23
SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene (2014) 1.23
Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev (2008) 1.22
Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle (2008) 1.20
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Epiblast/germ line hypothesis of cancer development revisited: lesson from the presence of Oct-4+ cells in adult tissues. Stem Cell Rev (2010) 1.17
Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα. Oncogene (2011) 1.17
MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci (2012) 1.17
Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway. Dis Model Mech (2010) 1.17
Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One (2011) 1.16
Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev (2014) 1.15
High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer. Oncotarget (2013) 1.15
Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res (2010) 1.15
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One (2010) 1.15
Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) (2009) 1.15
β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene (2014) 1.14
Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol (2012) 1.14
Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene (2012) 1.13
CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res (2012) 1.13
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int (2006) 1.11
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis (2010) 1.11
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget (2012) 1.11
Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res (2012) 1.11
Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia (2010) 1.11
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
The role of microRNAs in the regulation of cancer stem cells. Front Genet (2014) 1.09
The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cutan Pathol (2010) 1.09
The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther Targets (2010) 1.09
A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett (2013) 1.09
Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia (2008) 1.07
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet (2009) 2.65
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem (2002) 2.58
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol (2012) 2.31
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
The approach to the patient with a difficult melanocytic lesion. Pathology (2004) 2.12
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 2.06
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol (2006) 2.05
Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev (2004) 2.05
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol (2004) 1.90
Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol (2007) 1.89
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol (2013) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Stem cells with neural crest characteristics derived from the bulge region of cultured human hair follicles. J Invest Dermatol (2009) 1.85
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res (2005) 1.76
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell (2010) 1.76
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest (2008) 1.69
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol (2002) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell (2012) 1.63
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer (2003) 1.62
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol (2002) 1.55
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics (2011) 1.53
Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res (2010) 1.52
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat Protoc (2012) 1.51
Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci (2010) 1.48
Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res (2011) 1.47
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol (2005) 1.46
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet (2011) 1.46
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res (2002) 1.42
Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes. Cell Cycle (2008) 1.42
Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol (2007) 1.41
Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39